8-K: Vaxart Announces Third Quarter 2024 Financial Results and Business Update, Progressing COVID-19 and Norovirus Programs

Vaxart reports its Q3 2024 financial results, highlighting progress in its COVID-19 vaccine trial and norovirus program, with a focus on completing the sentinel cohort enrollment and evaluating next steps for norovirus.

Summary

• Vaxart announced its third quarter 2024 financial results, reporting a net loss of $14.1 million, an improvement from the $17.4 million loss in the same quarter of 2023.
• The company's revenue for the quarter was $4.9 million, up from $2.1 million in the third quarter of 2023, primarily due to government contracts related to BARDA.
• Research and development expenses were $15.1 million, slightly up from $15.0 million in the same period last year, driven by COVID-19 vaccine trial costs.
• Vaxart's cash, cash equivalents, and investments totaled $58.7 million as of September 30, 2024, with a projected cash runway into 2026.
• The company is nearing completion of the 400-participant sentinel cohort enrollment for its COVID-19 Phase 2b trial, with the potential to expand to 10,000 participants in early 2025 if safety data is favorable.
• Vaxart received feedback from the FDA on its norovirus program and is evaluating next steps, including new, potentially more potent constructs.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with improved financial results and progress in clinical trials, but there are still risks and uncertainties associated with the company's programs.

Positives

• Vaxart's revenue increased significantly year-over-year, driven by government contracts.
• The company's net loss decreased compared to the same quarter last year, indicating improved financial performance.
• Vaxart is making progress on its COVID-19 vaccine program, with the sentinel cohort enrollment nearing completion.
• The company has a solid cash position, providing a runway into 2026.
• Vaxart is actively working on improving its norovirus vaccine candidates with new, potentially more potent constructs.

Negatives

• Vaxart continues to operate at a loss, with a net loss of $14.1 million for the quarter.
• The FDA has requested new clinical data for the norovirus program before proceeding with further review of the potential correlate of protection.
• Research and development expenses remain high at $15.1 million for the quarter.

Risks

• The success of the COVID-19 Phase 2b trial is contingent on favorable safety data review by the FDA and DSMB.
• The norovirus program faces uncertainty due to the FDA's request for additional clinical data.
• The company's financial performance is dependent on continued government funding and successful clinical trial outcomes.
• There are inherent risks in research and development, including the ability to meet clinical endpoints and regulatory approval dates.

Future Outlook

Vaxart expects to complete enrollment of the sentinel cohort in November 2024 and, pending favorable safety data, initiate the 10,000-participant portion of the Phase 2b trial in early 2025. The company anticipates a cash runway into 2026.

Management Comments

• Steven Lo, Vaxart's CEO, stated that the successful initiation of sentinel cohort dosing is a testament to the company's rapid execution.
• Mr. Lo also mentioned that the company is pleased to be nearing completion of enrollment of the sentinel cohort.
• Mr. Lo added that the company received constructive feedback from the FDA on its proposed correlate of protection for the norovirus program and is evaluating next steps.

Industry Context

Vaxart's progress in developing oral vaccines aligns with the broader industry trend of exploring alternative vaccine delivery methods. The company's focus on mucosal technology and pill-based vaccines positions it as a potential disruptor in the vaccine market, particularly if it can demonstrate advantages over traditional injectable vaccines.

Comparison to Industry Standards

• Vaxart's Q3 2024 revenue of $4.9 million, primarily from government contracts, is a positive sign compared to other clinical-stage biotech companies that often rely solely on private funding.
• The company's net loss of $14.1 million is typical for a company in its stage of development, but the improvement from the previous year is encouraging.
• The cash runway into 2026 is a positive indicator of financial stability compared to other companies that may face near-term funding challenges.
• Vaxart's focus on oral vaccines is a differentiator compared to companies primarily developing injectable vaccines, such as Moderna and Pfizer, which are the current market leaders in mRNA COVID-19 vaccines.
• The company's norovirus program is in a competitive space with other companies developing norovirus vaccines, such as Takeda, but Vaxart's oral pill approach is a potential advantage.

Stakeholder Impact

• Shareholders may view the improved financial results and clinical progress positively.
• Employees may be encouraged by the company's progress and financial stability.
• Customers and partners may be interested in the potential of Vaxart's oral vaccine technology.
• Creditors may be reassured by the company's cash runway into 2026.

Next Steps

• Complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024.
• Review 30-day safety data of the sentinel cohort by the independent DSMB and the FDA.
• Initiate the 10,000-participant portion of the Phase 2b trial in early 2025, pending favorable safety data.
• Evaluate next steps for the norovirus program based on FDA feedback and new construct data.
• Continue discussions with key opinion leaders on the best way to progress the norovirus program.

Key Dates

Keywords

Vaxart, COVID-19 vaccine, norovirus vaccine, Phase 2b trial, BARDA, oral vaccine, clinical trial, financial results, biotechnology, FDA